Search Clinical Trials
Sponsor Condition of Interest |
---|
Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims Data
Pfizer
SARS-CoV-2
COVID-19
Post-Acute COVID-19 Syndrome
This study aims to use vaccination information from state vaccine registries linked with
HealthVerity insurance claims for the following:
- to measure how effective the Pfizer-BioNTech vaccine is at preventing post-COVID
conditions.
- to understand characteristics of patients who are r1 expand
This study aims to use vaccination information from state vaccine registries linked with HealthVerity insurance claims for the following: - to measure how effective the Pfizer-BioNTech vaccine is at preventing post-COVID conditions. - to understand characteristics of patients who are receiving COVID-19 vaccines. All patients whose information is kept unidentified in the HealthVerity database are eligible to be included for both aims of this study. Type: Observational Start Date: Oct 2023 |
Strategies and Treatments for Respiratory Infections &Amp; Viral Emergencies (STRIVE): Immune Modul1
University of Minnesota
COVID-19
COVID-19 can trigger a dysregulated immune response, and previous studies have shown that
immune modulation can improve outcomes in hospitalized patients. This trial is designed
to determine whether intensification of immune modulation early in the course of the
disease (while patients are on low f1 expand
COVID-19 can trigger a dysregulated immune response, and previous studies have shown that immune modulation can improve outcomes in hospitalized patients. This trial is designed to determine whether intensification of immune modulation early in the course of the disease (while patients are on low flow oxygen) with abatacept (active arm) combined with standard of care (SOC) improves recovery as compared with placebo + SOC (placebo arm). For both groups, intensification of immunomodulation will be provided as part of SOC in case of signs of disease progression (patient requires high flow nasal oxygen (HFNO) or more support) and/or if the patient has rapidly increasing oxygen requirement. Type: Interventional Start Date: Jul 2023 |
A Study of Ad26.COV2.S in Healthy Pregnant Participants (COVID-19)
Janssen Vaccines & Prevention B.V.
COVID-19 Prevention
The purpose of this study is to assess the safety and reactogenicity of Ad26.COV2.S
administered intramuscularly (IM) as a 1-dose schedule at the standard dose level in
adult participants during the second and/or third trimester of pregnancy and
(potentially) post-partum; to assess the humoral immu1 expand
The purpose of this study is to assess the safety and reactogenicity of Ad26.COV2.S administered intramuscularly (IM) as a 1-dose schedule at the standard dose level in adult participants during the second and/or third trimester of pregnancy and (potentially) post-partum; to assess the humoral immune response in peripheral blood of adult participants to Ad26.COV2.S administered IM as a 1-dose schedule during the second and/or third trimester of pregnancy, 28 days after vaccination. Type: Interventional Start Date: Aug 2021 |
A Synthetic MVA-based SARS-CoV-2 Vaccine, GEO-CM04S1, for the Prevention of COVID-19 Infection
GeoVax, Inc.
COVID-19 Infection
This phase I trial evaluates the side effects and best dose of GEO-CM04S1 (previously
designated as COH04S1), a synthetic modified vaccinia Ankara (MVA)-based SARS-CoV-2
vaccine, for the prevention of COVID-19 infection. COVID-19 infection is caused by the
SARS-CoV-2 virus. SARS-CoV-2 has demonstra1 expand
This phase I trial evaluates the side effects and best dose of GEO-CM04S1 (previously designated as COH04S1), a synthetic modified vaccinia Ankara (MVA)-based SARS-CoV-2 vaccine, for the prevention of COVID-19 infection. COVID-19 infection is caused by the SARS-CoV-2 virus. SARS-CoV-2 has demonstrated the capability to spread rapidly, leading to significant impacts on healthcare systems and causing societal disruption. GEO-CM04S1 was created by placing small pieces of SARS-CoV-2 DNA (the chemical form of genes) into synthetic MVA, which may be able to induce immunity (the ability to recognize and fight against an infection) to SARS-CoV-2. The purpose of the Phase 1 study is to determine the safety and the optimal dose of the GEO-CM04S1 vaccine. The Phase 2 study is designed as a multi-center, double-blind, randomized, parallel, study to evaluate the safety profile of 2 dose levels of GEO-CM04S1 as a single booster shot to assess the immune response measured by the fold-increase in antibody against SARS-CoV-2 Spike protein at day 28 post-injection among healthy adult volunteers. Type: Interventional Start Date: Nov 2020 |
A Drug-drug Interaction Study of S-892216 Coadministered With Carbamazepime to Healthy Adult Partic1
Shionogi
COVID-19
The primary objective of this study is to investigate the effect of multiple-dose
administration of carbamazepine on the pharmacokinetics of S-892216 in healthy adults. expand
The primary objective of this study is to investigate the effect of multiple-dose administration of carbamazepine on the pharmacokinetics of S-892216 in healthy adults. Type: Interventional Start Date: Dec 2024 |
A Phase 2b, Randomized, Double-blind, Active-controlled Study of Single Dose CVXGA Intranasal COVID1
CyanVac LLC
COVID-19
The purpose of this trial is to assess the safety and relative efficacy of CVXGA
(CVXGA50), a KP.2 containing vaccine, compared to COMIRNATY® (COVID-19 Vaccine, mRNA;
2024-2025 Formula), a currently approved COVID-19 vaccine in the prevention of
symptomatic, RT-PCR-confirmed SARS-CoV-2 infection. T1 expand
The purpose of this trial is to assess the safety and relative efficacy of CVXGA (CVXGA50), a KP.2 containing vaccine, compared to COMIRNATY® (COVID-19 Vaccine, mRNA; 2024-2025 Formula), a currently approved COVID-19 vaccine in the prevention of symptomatic, RT-PCR-confirmed SARS-CoV-2 infection. The trial will enroll up to 10016 healthy participants. Type: Interventional Start Date: Dec 2024 |
A Strain Change Study for SARS-CoV-2 rS Vaccines
Novavax
Severe Acute Respiratory Syndrome Coronavirus 2 Infection
The present study aims to investigate the safety and immunogenicity of the Novavax JN.1
subvariant vaccine SARS-CoV-2 rS adjuvanted with Matrix-M (NVX CoV2705) in previously
vaccinated adults. A descriptive comparison will be made with participants who received
the prior authorized vaccine NVX-CoV21 expand
The present study aims to investigate the safety and immunogenicity of the Novavax JN.1 subvariant vaccine SARS-CoV-2 rS adjuvanted with Matrix-M (NVX CoV2705) in previously vaccinated adults. A descriptive comparison will be made with participants who received the prior authorized vaccine NVX-CoV2601 in an earlier study (2019nCoV-313). Type: Interventional Start Date: Oct 2024 |
Post-marketing Safety of Elasomeran/Davesomeran and Andusomeran
ModernaTX, Inc.
SARS-CoV-2
The main objective of the study is to evaluate the safety of the elasomeran/davesomeran
and andusomeran vaccines as used in routine clinical practice. expand
The main objective of the study is to evaluate the safety of the elasomeran/davesomeran and andusomeran vaccines as used in routine clinical practice. Type: Observational Start Date: Apr 2023 |
Narrative Intervention for Long COVID-19 (NICO)
University of Colorado, Denver
Long COVID
Long Covid19
This T1 proof of concept trial is designed to test the Narrative Intervention for Long
COVID-19 intervention. expand
This T1 proof of concept trial is designed to test the Narrative Intervention for Long COVID-19 intervention. Type: Interventional Start Date: Oct 2022 |
Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS Vaccin1
Novavax
COVID-19
This is a Phase 2/3, randomized, double-blind study to evaluate the safety and
immunogenicity of different booster dose levels of the monovalent severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) recombinant (r) spike (S) protein
nanoparticle (SARS-CoV-2 rS) vaccines with Matrix-M™ adjuva1 expand
This is a Phase 2/3, randomized, double-blind study to evaluate the safety and immunogenicity of different booster dose levels of the monovalent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) recombinant (r) spike (S) protein nanoparticle (SARS-CoV-2 rS) vaccines with Matrix-M™ adjuvant (NVX-CoV2373 [prototype Wuhan vaccine with Matrix-M adjuvant] or NVX-CoV2601 [Omicron XBB.1.5 subvariant vaccine with Matrix-M adjuvant]). Type: Interventional Start Date: Oct 2023 |
Open Label Extension of Efgartigimod in Adults with Post-COVID-19 POTS
argenx
Post-COVID Postural Orthostatic Tachycardia Syndrome Postural Orthostatic Tachycardia Syndrome
The OLE study aims to investigate the safety, efficacy, pharmacodynamics (PD),
pharmacokinetics (PK), and immunogenicity of efgartigimod in participants with
post-COVID-19 postural orthostatic. expand
The OLE study aims to investigate the safety, efficacy, pharmacodynamics (PD), pharmacokinetics (PK), and immunogenicity of efgartigimod in participants with post-COVID-19 postural orthostatic. Type: Interventional Start Date: Jun 2023 |
Study of VXCO-100, a SARS-CoV Candidate Vaccine in Healthy Adults in the United States
Vaccine Company, Inc.
SARS-CoV
SARS-CoV-2
The purpose of this study is to evaluate the safety and immunogenicity of ascending dose
levels of VXCO-100 in healthy adults. expand
The purpose of this study is to evaluate the safety and immunogenicity of ascending dose levels of VXCO-100 in healthy adults. Type: Interventional Start Date: May 2023 |
RADx-UP- Impact of Community Health Worker Deployment
Morehouse School of Medicine
Diabetes
COVID-19
Community Health Workers
Health Behavior
Health Knowledge, Attitudes, Practice
The proposed project will implement and evaluate a brief Community Health Worker (CHW)
intervention through the Albany Area Primary Health Care, a rural Federally Qualified
Health Center (FQHC). The primary goal of this study is to maximize effective outreach,
education, and communication through C1 expand
The proposed project will implement and evaluate a brief Community Health Worker (CHW) intervention through the Albany Area Primary Health Care, a rural Federally Qualified Health Center (FQHC). The primary goal of this study is to maximize effective outreach, education, and communication through CHWs in order to facilitate improved COVID-19 vaccine confidence and uptake in underserved and vulnerable communities. CHWs will be deployed to the homes of adults with increased risk of morbidity and mortality (i.e., African Americans or Latinos with uncontrolled diabetes or prediabetes, age <50 years, and non-COVID-19 vaccinated) in order to educate them about diabetes, COVID-19 and related vaccines. Health assessments, including blood glucose measurement, will be conducted on the indexed patient and offered to all other adult family members in the household (i.e., "bubble"). Adults with Type 2 diabetes likely live in households with other adults who have or are at increased risk for diabetes (i.e., prediabetes and obesity).1 It is expected that they will also share similar COVID-19 exposure risk. The specific aims are to: 1) Evaluate a community-driven education program to increase and enhance COVID-19 vaccine confidence and uptake in individuals with uncontrolled diabetes and their families (i.e., their "bubble") and 2) Evaluate a community-driven education program to improve diabetes self-management behaviors and related outcomes (e.g., blood glucose) in individuals with uncontrolled diabetes in rural, Southwest Georgia. Type: Interventional Start Date: Feb 2022 |
A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults
ModernaTX, Inc.
SARS-CoV-2
Influenza
The study is divided into 2 parts: Part 1 and Part 2. The purpose of Part 1 of this study
is to generate sufficient safety, reactogenicity, and immunogenicity data to enable
selection of an mRNA-1083 vaccine composition and dose level to evaluate in a subsequent
Phase 3 clinical trial in adults.
T1 expand
The study is divided into 2 parts: Part 1 and Part 2. The purpose of Part 1 of this study is to generate sufficient safety, reactogenicity, and immunogenicity data to enable selection of an mRNA-1083 vaccine composition and dose level to evaluate in a subsequent Phase 3 clinical trial in adults. The purpose of Part 2 of this study is to generate safety and immunogenicity data for additional mRNA-1083 compositions and dose levels in young adults ≥18 years and <50 years of age. Type: Interventional Start Date: Apr 2023 |
Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study: Study Under1
AstraZeneca
COVID-19, SARS-CoV-2
AZD3152, a single mAb, is being developed to have broad neutralizing activity across
known SARS-CoV-2 variants of concern for pre-exposure prophylaxis of COVID-19.
The aim of the Phase I/III study (Parent Study) will be to evaluate the safety, efficacy
and neutralizing activity of AZD3152 compared1 expand
AZD3152, a single mAb, is being developed to have broad neutralizing activity across known SARS-CoV-2 variants of concern for pre-exposure prophylaxis of COVID-19. The aim of the Phase I/III study (Parent Study) will be to evaluate the safety, efficacy and neutralizing activity of AZD3152 compared with comparator for pre exposure prophylaxis of COVID-19, and separately evaluate the safety and PK of AZD5156, a combination of AZD3152 and AZD1061. Sub-study: This Phase II sub-study of SUPERNOVA will assess the safety, PK, and predicted neutralizing activity of AZD3152 compared with EVUSHELD for pre-exposure prophylaxis of COVID-19. Type: Interventional Start Date: Dec 2022 |
Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-1
ModernaTX, Inc.
SARS-CoV-2
The study will evaluate the safety, tolerability, reactogenicity, and effectiveness of
mRNA-1273.214 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine in
infants aged 12 weeks to < 6 months. expand
The study will evaluate the safety, tolerability, reactogenicity, and effectiveness of mRNA-1273.214 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine in infants aged 12 weeks to < 6 months. Type: Interventional Start Date: Sep 2022 |
Exercise in Child Health
University of California, Irvine
Cystic Fibrosis
Sickle Cell Disease
SARS CoV 2 Infection
This study is a cooperative investigation funded by the NIH. The project is a
collaboration among three major NIH Clinical Translational Science Awardees: 1) UCI (lead
site with its affiliate CHOC), 2) Northwestern University (with its affiliate Lurie
Children's Hospital), and 3) USC (with its affi1 expand
This study is a cooperative investigation funded by the NIH. The project is a collaboration among three major NIH Clinical Translational Science Awardees: 1) UCI (lead site with its affiliate CHOC), 2) Northwestern University (with its affiliate Lurie Children's Hospital), and 3) USC (with its affiliate Children's Hospital of Los Angeles). There is an increasing number of children who, through medical advances, now survive diseases and conditions that were once fatal, but which remain chronic and debilitating. A major challenge to improve both the immediate and long term care and health of such children has been the gap in our understanding of how to assess the biological effects of exercise. Like otherwise healthy children, children with chronic diseases and disabilities want to be physically active. The challenge is to determine what constitutes safe and beneficial level of physical activity when the underlying disease or condition [e.g., cystic fibrosis (CF) or sickle cell disease (SCD)] imposes physiological constraints on exercise that are not present in otherwise healthy children. Current exercise testing protocols were based on studies of athletes and high performing healthy individuals and were designed to test limits of performance at very high-intensity, unphysiological, maximal effort. These approaches are not optimal for children and adolescents with disease and disability. This project (REACH-Revamping Exercise Assessment in Child Health) is designed to address this gap. Cohorts of children will be identified with two major genetic diseases (CF and SCD) and measure exercise responses annually as they progress from early puberty to mid or late puberty over a 3-4year period. In addition, in the light of the pandemic, a group of children will be added who were affected by SARS-CoV-2 and investigate their responses to exercise. SARS-CoV-2 has similar long-term symptoms than CF and SCD have. Novel approaches to assessing physiological responses to exercise using advanced data analytics will be examined in relation to metrics of habitual physical activity, circulating biomarkers of inflammation and growth, leukocyte gene expression, and the impact of the underlying CF, SCD or SARS-CoV-2 condition. The data from this study will help to develop a toolkit of innovative metrics for exercise testing that will be made available to the research and clinical community. Type: Interventional Start Date: Nov 2020 |
The SINCERE Intervention to Address COVID-19 Health Disparities
Andrea Wallace
COVID-19
Vulnerable Populations
Social Determinants of Health
The goal of this real world efficacy study is to understand the benefit of universal
social needs screening, community-based service referrals, and telephonic follow-up as a
scalable strategy for preventing COVID-19 transmission, and for addressing the secondary
health effects of the social, behavi1 expand
The goal of this real world efficacy study is to understand the benefit of universal social needs screening, community-based service referrals, and telephonic follow-up as a scalable strategy for preventing COVID-19 transmission, and for addressing the secondary health effects of the social, behavioral, and economic changes following the COVID-19 pandemic. With statewide community service providers, existing health information technology, and piloted methods, we seek to determine the effectiveness of universal social needs screening and community service referrals - the SINCERE intervention - in improving health outcomes of COVID-19 vulnerable and socioeconomically disadvantaged populations and whether intensive follow-up and collaborative goal-setting helps overcome barriers to community service use by patients seen in the emergency department and seeking COVID testing at community-based and mobile clinic locations. Type: Interventional Start Date: Sep 2021 |
Evaluation of Point-of-Care (EPOC) for COVID-19
University of Minnesota
COVID-19
SARS CoV 2 Infection
EPOC is designed to examine the feasibility of conducting two point-of-care (POC) tests
the LumiraDx SARS-CoV-2 Antibody Test and the RightSign COVID-19 IgG/IgM Rapid Test for
SARS-CoV-2 antibodies and compare the reproducibility of these tests to tests run at a
central laboratory on specimens obta1 expand
EPOC is designed to examine the feasibility of conducting two point-of-care (POC) tests the LumiraDx SARS-CoV-2 Antibody Test and the RightSign COVID-19 IgG/IgM Rapid Test for SARS-CoV-2 antibodies and compare the reproducibility of these tests to tests run at a central laboratory on specimens obtained from the same study participants at the same time. Type: Observational Start Date: Apr 2022 |
Assessing Testing Strategies for Safe Return to K-12 Schools in an Underserved Population
Washington University School of Medicine
Covid19
The primary goal of this study is to determine the most effective SARS-CoV-2 testing
strategy for successful return of in-person school in the under-served communities of St.
Louis.
Regular screening testing has been recommended by the CDC as an additive mitigation
strategy for in-person schools i1 expand
The primary goal of this study is to determine the most effective SARS-CoV-2 testing strategy for successful return of in-person school in the under-served communities of St. Louis. Regular screening testing has been recommended by the CDC as an additive mitigation strategy for in-person schools in areas of high community transmission. We will compare the effectiveness and acceptance of two different school-based testing strategies among students and school staff (symptomatic testing only versus weekly surveillance testing plus symptomatic testing), measuring school-based SARS-CoV-2 transmission through a cluster randomized trial. Type: Interventional Start Date: May 2021 |
Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic1
Kristin Hudock
COVID 19
SARS-CoV 2
Pneumonia
The purpose of this prospective, Phase 2, multicenter, blinded, randomized placebo
controlled study is to demonstrate that early treatment with mavrilimumab prevents
progression of respiratory failure in patients with severe COVID-19 pneumonia and
clinical and biological features of hyper-inflammat1 expand
The purpose of this prospective, Phase 2, multicenter, blinded, randomized placebo controlled study is to demonstrate that early treatment with mavrilimumab prevents progression of respiratory failure in patients with severe COVID-19 pneumonia and clinical and biological features of hyper-inflammation. Type: Interventional Start Date: May 2020 |
Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients
Novartis Pharmaceuticals
Sickle Cell Disease (SCD)
The purpose of the Phase 2 CSEG101B2201 study is to confirm and to establish appropriate
dosing and to evaluate the safety in pediatric participants ages 6 months to <18 years
with a history of VOC with or without HU/HC, receiving crizanlizumab for 2 years. The
efficacy and safety of crizanlizumab1 expand
The purpose of the Phase 2 CSEG101B2201 study is to confirm and to establish appropriate dosing and to evaluate the safety in pediatric participants ages 6 months to <18 years with a history of VOC with or without HU/HC, receiving crizanlizumab for 2 years. The efficacy and safety of crizanlizumab was already demonstrated in adults with sickle cell disease. The approach is to extrapolate from the PK/pharmacodynamics (PD) already established in the adult population. The study is designed as a Phase II, multicenter, open-label study. Type: Interventional Start Date: Oct 2018 |
COVID-19 Associated Lymphopenia Pathogenesis Study in Blood
National Institute of Allergy and Infectious Diseases (NIAID)
Coronavirus Disease 2019
Background:
COVID-19 is an acute respiratory syndrome. One symptom of COVID-19 is a reduction in the
number of cells called lymphocytes in the blood. Lymphocytes are a type of white blood
cell that fights infections. With fewer lymphocytes, the body cannot effectively fight
back against SARS CoV-21 expand
Background: COVID-19 is an acute respiratory syndrome. One symptom of COVID-19 is a reduction in the number of cells called lymphocytes in the blood. Lymphocytes are a type of white blood cell that fights infections. With fewer lymphocytes, the body cannot effectively fight back against SARS CoV-2, the virus that causes COVID-19. Researchers want to better understand how SARS-CoV-2 affects these blood cells. This information may give them ideas for new treatments. Objective: To learn more about how SARS-CoV-2 affects lymphocytes, the immune, and the blood clotting system. Eligibility: Adults age 18 and older who either currently have COVID-19 or have recently recovered from it Design: Participants will give a blood sample. For this, a needle is used to collect blood from an arm vein. For participants who have a central line, blood will be collected through that instead. Participants medical records related to COVID-19 will be reviewed. Participants who have recovered from COVID-19 will be asked to undergo leukapheresis to collect white blood cells. For this, blood is taken from a needle placed in one arm. A machine separates out the white blood cells. The rest of the blood is returned to the participant through a needle placed in the other arm. This takes about 2-3 hours. Recovered participants may have material collected from inside the nostrils and/or rectum. This is done by gently rubbing the area with a sterile cotton swab. Recovered participants may have an echocardiogram to look at their heart. For this, a small probe is held against the chest to get pictures of the heart from different angles. This takes less than 30 minutes. Participation lasts 1-2 days on most cases and may be split in a few visits for recovered patients if leukapheresis and echocardiogram are done. ... Type: Observational Start Date: May 2020 |
An Observational Study of Neurologic Function After COVID-19 Infection
National Institute of Neurological Disorders and Stroke (NINDS)
COVID-19
Background:
COVID-19 is an infection caused by a coronavirus. It can affect different parts of the
body. For most people, it causes fevers or trouble breathing. Some people can have
symptoms long after they recover. Researchers want to learn if there are signs of changes
in the nervous system that1 expand
Background: COVID-19 is an infection caused by a coronavirus. It can affect different parts of the body. For most people, it causes fevers or trouble breathing. Some people can have symptoms long after they recover. Researchers want to learn if there are signs of changes in the nervous system that may be related to COVID-19. Objective: To test the nervous system (the brain and nerves) in people who have had COVID-19 yet still have certain symptoms even after recovering. Eligibility: People age 18 and older who had COVID-19 and still have neurologic symptoms after they recovered from the initial infection. Design: Participants will be screened with a medical record review. Participants will have a neurological exam. They will complete pen-and-paper tests of their memory and thinking. They will complete a smell test with 'scratch-and-sniff' booklets. They will give blood samples. Participants will have magnetic resonance imaging (MRI) of the brain. Soft padding or a coil will be placed around their head. They will lie on a table that slides in and out of the MRI scanner. They will get a contrast dye through an intravenous (IV) catheter. Participants blood pressure, blood flow, skin temperature, sweating, and breathing will be monitored. Participants will have an electrocardiogram to measure heart function. Participants will blow into a mouthpiece for several seconds. Participants will lie on a table that has a motor. The motor tilts the table. Participants will have blood drawn through an IV as the table tilts. Participants will have a lumbar puncture. A small needle will be inserted into the spinal canal to obtain fluid. Participants may repeat some tests 8 weeks to 1 year later. Type: Observational Start Date: Oct 2020 |
COVID-19 Pandemic Impact on Alcohol (PIA) - A Natural History Study
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Alcohol Drinking
Alcohol-Related Disorders
Pandemic
Psychological Stress
Background:
The SARS-CoV-2 virus has caused a pandemic infection called COVID-19. It is a global
threat to people, communities, and health systems. Researchers are concerned about the
mental health effects of the pandemic. They want to learn more about how it is affecting
people s alcohol use and1 expand
Background: The SARS-CoV-2 virus has caused a pandemic infection called COVID-19. It is a global threat to people, communities, and health systems. Researchers are concerned about the mental health effects of the pandemic. They want to learn more about how it is affecting people s alcohol use and problems, and how it may continue to affect them over time. Objective: To study the impact of the COVID-19 pandemic on alcohol use and consequences in individuals across the spectrum of alcohol use and those with alcohol use disorder. Eligibility: Participants who have been screened under the NIAAA Screening, Assessment and Management Protocol (14-AA-0181) Design: Participants will complete a baseline survey by phone. It will ask about alcohol use, alcohol dependence, and stress. It covers 2 time periods: the 12 months before the pandemic started and the time since it started. Participants will get an ID code and a link to an online survey. They will complete the online survey within a week of the phone survey. Participants will complete a series of online surveys over 24 months. For the first year, surveys will be completed weekly for the first 4 weeks, then biweekly for the next 8 weeks, and then every 1-2 months for the rest of the year. For the second year, surveys will be completed every 6 months. Surveys will cover the following topics: - Alcohol use and its consequences - Other substance use - Stress - Impact of the COVID-19 pandemic - Pain - Physical health - Sleep - Quality of life. Because the course of the pandemic may change, the frequency of the surveys may change. Participation lasts 2 years. Type: Observational Start Date: Jun 2020 |
- Previous
- Next